Phill Peter O'Neill

Personal Details

First Name:	Phill
Middle Name:	Peter
Last Name:	O'Neill
Suffix:
RePEc Short-ID:	pon103
	http://ohe.org

Affiliation

Office of Health Economics

London, United Kingdom
http://www.ohe.org/
RePEc:edi:ohecouk (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

Sorry, no citations of working papers recorded.

Articles

1. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
   • Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.

   Cited by:

   1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
   2. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
   3. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
   4. Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch, 2017. "Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)," PharmacoEconomics - Open, Springer, vol. 1(4), pages 255-263, December.
   5. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
   6. Olina Efthymiadou, 2023. "Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1023-1031, September.
   7. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
   8. Benedikt Schoser & Andreas Hahn & Emma James & Digant Gupta & Matthew Gitlin & Suyash Prasad, 2019. "A Systematic Review of the Health Economics of Pompe Disease," PharmacoEconomics - Open, Springer, vol. 3(4), pages 479-493, December.
   9. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
      • Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
   10. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
   11. Carlos K. H. Wong & Brian H. H. Lang & Vivian Y. W. Guo & Cindy L. K. Lam, 2016. "Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 647-657, December.
   12. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
   13. Pieter Baal & Alec Morton & David Meltzer & Werner Brouwer, 2019. "Future unrelated medical costs need to be considered in cost effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 1-5, February.
   14. Francesco Paolucci & Ken Redekop & Ayman Fouda & Gianluca Fiorentini, 2017. "Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage," Applied Health Economics and Health Policy, Springer, vol. 15(6), pages 697-706, December.
   15. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018. "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(11), pages 1345-1353, November.
   16. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
   17. M. J. Walton & J. O’Connor & C. Carroll & L. Claxton & R. Hodgson, 2019. "A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process," PharmacoEconomics - Open, Springer, vol. 3(3), pages 403-410, September.
   18. Carlos King Ho Wong & Olivia Wu & Bernard M. Y. Cheung, 2018. "Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 5-14, February.
   19. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
   20. Shiroiwa, Takeru & Fukuda, Takashi & Ikeda, Shunya & Takura, Tomoyuki, 2017. "New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations," Health Policy, Elsevier, vol. 121(8), pages 836-841.
   21. Angela Rocchi & Elizabeth Miller & Robert Hopkins & Ron Goeree, 2012. "Common Drug Review Recommendations," PharmacoEconomics, Springer, vol. 30(3), pages 229-246, March.
   22. Kerr, Anne & Hill, Rosemary L. & Till, Christopher, 2018. "The limits of responsible innovation: Exploring care, vulnerability and precision medicine," Technology in Society, Elsevier, vol. 52(C), pages 24-31.

Books

Sorry, no citations of books recorded.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Phill Peter O'Neill should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.